Effect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 5-6, 2009, Pages 501-508

  Khan, Abdul H ^b   Sattar, Munavvar A ^c   Abdullah, Nor A ^d   Johns, Edward J ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^d UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Amlodipine; Cisplatin; Early diabetic nephropathy; Nephrotoxic renal failure

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; METHOXAMINE; NORADRENALIN; PHENYLEPHRINE; SODIUM; STREPTOZOCIN;

ADRENERGIC ACTIVITY; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; GLOMERULUS FILTRATION; KIDNEY ARTERY VASOCONSTRICTION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; MALE; NONHUMAN; RAT; SODIUM EXCRETION; VASOCONSTRICTION;

AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GLOMERULAR FILTRATION RATE; KIDNEY; KIDNEY DISEASES; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC; RENAL CIRCULATION; RENAL INSUFFICIENCY; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 65349142430     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05098.x     Document Type: Article

References (42)

1. Walsh MP. Regulation of vascular smooth muscle tone. Can. J. Physiol. Pharmacol. 1994 72 : 919 36. (Pubitemid 24336849)
2. Missiaen L, De Smedt H, Droogmans G. Calcium ion homeostasis in smooth muscle. Pharmacol. Ther. 1992 56 : 191 223. (Pubitemid 23085320)
3. Ogawa N, Kushida H, Satoh S. Effect of verapamil on renal vasoconstriction induced by angiotensin II, norepinephrine or renal nerve stimulation in anesthetized dogs. Arch. Int. Pharmacodyn. Ther. 1984 268 : 113 21. (Pubitemid 14133761)
4. Takahara A, Dohmoto H, Hisa H. Cilnidipine attenuates renal nerve stimulation induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Jpn. J. Pharmacol. 1997 75 : 27 32. (Pubitemid 27462572)
5. Armenia A, Munavvar AS, Abdullah NA, Helmi A, Johns EJ. The contribution of adrenoceptor subtype(s) in the renal vasculature of diabetic spontaneously hypertensive rats. Br. J. Pharmacol. 2004 142 : 719 26. (Pubitemid 38976511)
6. 1-adrenoceptor subtypes in the cardiac failure in spontaneously hypertensive rats. J. Basic Appl. Sci. 2006 2 : 59 69.
7. Abbas SA, Munavvar AS, Abdullah NA, Johns EJ. Role of alpha1-adrenoceptor subtypes in renal haemodynamics in heart failure and diabetic SD rats. Can. J. Pure Appl. Sci. 2007 1 : 21 34.
8. Haragsim L, Zima T, Nemecek K. Nephrotoxic effect of platinum cytostatics-preventive effects of nifedipine and cimetidine. Sb. Lek. 1994 95 : 173 83.
9. Zima T, Nemecek K, Hatle K, Bartova V, Stipek S. The effects of calcium channel blockers on cylosporine A (Cs A) induced nephrotoxicity in rats. Sb. Lek. 1995 96 : 15 21.
10. Chander V, Chopra K. Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress and nephrotoxicity induced by cylosporine. Renal Fail. 2005 27 : 441 50. (Pubitemid 40993695)
11. Konda T, Enomoto A, Takahara A et al. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol. Pharm. Bull. 2006 29 : 933 7.
12. Rump LC. The role of sympathetic nervous activity in chronic renal failure. J. Clin. Basic Cardiol. 2001 4 : 179 82. (Pubitemid 33029252)
13. Phillips JK. Pathogenesis of hypertension in renal failure: Role of the sympathetic nervous system and renal afferents. Clin. Exp. Pharmacol. Physiol. 2005 32 : 415 18. (Pubitemid 40780268)
14. Kang DG, Lee AS, Mun YJ et al. Butein ameliorate renal concentrating ability in cisplatin-induced acute renal failure. Biol. Pharm. Bull. 2004 27 : 366 70. (Pubitemid 41685481)
15. Shimeda Y, Hirotani Y, Akimoto Y. Protective effect of capsiacin against cisplatin-induced nephrotoxicity in rats. Biol. Pharm. Bull. 2005 28 : 1635 8. (Pubitemid 41324123)
16. Hye Khan MA, Sattar MA, Abdullah NA, Johns EJ. Cisplatin cause altered renal hemodynamics in rats: Role of augmented α-adrenergic responsiveness. Exp. Toxicol. Pathol. 2007 53 : 253 60.
17. Khan AH, Sattar MA, Abdullah NA, Johns EJ. Influence of cisplatin-induced renal failure on the alpha(1)-adrenoceptor subtype causing vasoconstriction in the kidney of the rat. Eur. J. Pharmacol. 2007 569 : 110 18. (Pubitemid 47175868)
18. White RE, Carrier GO. Enhanced vascular α-adrenergic neuroeffector system in diabetes: Importance of calcium. Am. J. Physiol. 1988 255 : H1036 42. (Pubitemid 19009993)
19. Weber LP, Macleod KM. Influence of streptozotocin diabetes on the alpha-1 adrenoceptor and associated G proteins in rat arteries. J. Pharmacol. Exp. Ther. 1997 283 : 1469 78. (Pubitemid 28016523)
20. Abebe W, Harris KH, Macleod KM. Enhanced contractile responses of arteries from diabetic rats to alpha1-adrenoceptor stimulation in the absence and presence of extracellular calcium. J. Cardiovasc. Pharmacol. 1990 16 : 239 48. (Pubitemid 20222646)
21. 2+ in the selective enhancement of contractile responses of arteries from diabetic rats to noradrenaline. Can. J. Physiol. Pharmacol. 1994 72 : 1544 51.
22. Duggan KA, Hodge G, Makarious MM, Charlesworth JA. Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy. Clin. Exp. Pharmacol. Physiol. 1996 23 : 608 10. (Pubitemid 26186456)
23. Lehfeld LS, Silveira LA, Ghini B. Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy. Kidney Blood Press. Res. 2004 27 : 114 20. (Pubitemid 38594563)
24. Isogai S, Kameyama M, Iso K, Yoshino G. Protective effects of a small dose of captopril on the reduction of glomerular basement membrane anionic sites in spontaneously hypertensive rats with streptozotocin-induced diabetes. J. Diabetes Complications 1998 12 : 170 3. (Pubitemid 28241442)
25. Gojo A, Utsunomiya K, Tanigushi K et al. The Rho-kinase inhibitor, fasudil attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2007 568 : 242 7. (Pubitemid 46976901)
26. Qian LU, Yin X, Wang J, Gao Y, Pan Y. Effects of Ginkgo biloba on prevention of development of experimental diabetic nephropathy in rats. Acta Pharmacol. Sin. 2007 28 : 818 28. (Pubitemid 46817438)
27. Yin X, Zhang Y, Shen J et al. Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats. Acta Pharmacol. Sin. 2005 26 : 721 8. (Pubitemid 40806562)
28. Zhang Y-W, Wu C-Y, Cheng J-T. Merit of Astragalus plysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expression of NF-κB and IκB in renal cortex of streptozotocin-induced diabetic rats. J. Ethnopharmacol. 2007 114 : 387 92. (Pubitemid 350026214)
29. Yin X, Zhang Y, Yu J et al. The antioxidant effects of Astragalus saponin I protect against development of early diabetic nephropathy. J. Pharmacol. Sci. 2006 101 : 166 73. (Pubitemid 43938768)
30. 1-Adrenoceptor subtype mediating adrenergic vasoconstriction in kidney of 2K1C Goldblatt and DOCA-salt hypertensive rats. J. Cardiovasc. Pharmacol. 1994 24 : 420 8.
31. 1-adrenoceptor subtype mediating adrenergic vasoconstriction in Wistar normotensive and stroke-prone spontaneously hypertensive rat kidney. J. Cardiovasc. Pharmacol. 1994 23 : 232 9. (Pubitemid 24032572)
32. 1A-adrenoceptors in contraction of rat mesenteric artery. Vasc. Pharmacol. 2003 40 : 91 6. (Pubitemid 37329345)
33. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens. Res. 1996 19 : 31 6. (Pubitemid 26134958)
34. Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dhal rats. Hypertens. Res. 2003 26 : 635 41. (Pubitemid 37086636)
35. Salomonsson M, Arendshorst WJ. Calcium recruitment in the renal vasculature: Norepinephrine effects on blood flow and cytosolic calcium concentration. Am. J. Physiol. 1999 276 : F700 10. (Pubitemid 29249689)
36. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002 106 : 1974 9. (Pubitemid 35176304)
37. Fujii T, Kurata H, Takaoka M et al. The role of sympathetic nervous system in the pathogenesis of ischemic acute renal failure. Eur. J. Pharmacol. 2003 481 : 241 8. (Pubitemid 37464976)
38. Fujii T, Sugiura T, Ohkita M, Kobuchi S, Takoaka M, Matsumura Y. Slective antagonism of the post-synaptic α-adrenoceptor is protective against ischemic acute renal failure in rats. Eur. J. Pharmacol. 2007 574 : 185 91. (Pubitemid 47575520)
39. Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomised rats. J. Am. Soc. Nephrol. 2000 11 : 1469 78. (Pubitemid 30483463)
40. Usui H, Shikata K, Matsuda M et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol. Dial. Transplant. 2003 18 : 266 72. (Pubitemid 36181675)
41. Pflueger AC, Larson TS, Hagl S, Knox FG. Role of nitric oxide in intrarenal hemodynamics in experimental diabetes mellitus in rats. Am. J. Physiol. 1999 277 : R725 33. (Pubitemid 29458144)
42. 1-adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released in rat femoral resistance arteries. Br. J. Pharmacol. 2004 141 : 915 24. (Pubitemid 38510074)